Veracyte Goodwill

The latest goodwill for VCYT is $770M as of June 2026. That compares with $770M in the prior-year period — down 0.8% year over year. Investors often review this figure alongside Veracyte's historical trend and sector peers before judging valuation or financial health.

Over the past year, VCYT's goodwill moved from $770M to $770M — a 0.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Veracyte's operating scale or balance-sheet position.

A goodwill figure of $770M for VCYT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting VCYT's goodwill ($770M), review year-over-year change from $770M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Veracyte's goodwill against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.